Entero Healthcare Solutions Limited has informed the Exchange regarding Outcome of Board Meeting held on May 25, 2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions reported audited financial results for FY2026. Consolidated revenue grew 29.3% year-on-year to Rs 65,912.12 million, with net profit up 35.7% to Rs 1,458.40 million. Standalone revenue stood at Rs 3,482.41 million with net profit of Rs 268.75 million. The Board approved re-appointment of three Independent Directors for a second term of five years (subject to shareholder approval), allotted 7,240 equity shares under the ESOP plan, and granted 7,300 fresh stock options. The 8th AGM is scheduled for August 19, 2026. The company also announced acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through its subsidiary Sai Pharma Distributors Private Limited. Auditors expressed unmodified opinion on both standalone and consolidated results.
Strong financial performance with 35.7% profit growth signals operational strength. ESOP activities and acquisitions indicate continued expansion strategy. The unmodified audit opinion provides clean financials assurance.